GO:0036018 cellular response to erythropoietin: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036018 (cellular response to erythropoietin) describes all molecular and cellular changes triggered when a cell encounters erythropoietin (EPO).
• The canonical response involves EPO binding to its receptor (EPOR), activation of JAK2/STAT5 signaling, and downstream transcriptional programs that drive erythroid survival, proliferation, and differentiation.
• Dysregulated EPO responses contribute to anemia of chronic disease, myelodysplastic syndromes, and resistance to erythropoiesis-stimulating agents.
• Tumor-derived EPO can act as an immunosuppressive switch in the tumor microenvironment, highlighting non-erythroid roles of this pathway.
• Impaired EPO response to hypoxia is observed in type 2 diabetes, linking metabolic disease to defective erythropoiesis.
• CRISPR-based models (knockout, knock-in, point mutation) enable precise dissection of EPO/EPOR signaling components and their roles in disease.
Description
Erythropoietin (EPO) is a glycoprotein hormone primarily produced by the kidney in response to hypoxia, and it orchestrates red blood cell production by binding to the erythropoietin receptor (EPOR) on erythroid progenitor cells. The cellular response to erythropoietin (GO:0036018) encompasses the full set of intracellular events that occur after EPO stimulation, including receptor activation, kinase signaling, changes in gene expression, and alterations in cell survival, proliferation, and differentiation. This process is essential for maintaining oxygen homeostasis and is a major therapeutic target in anemias and myelodysplastic syndromes. Beyond erythropoiesis, EPO signaling has been implicated in non-hematopoietic tissues, including the immune system and the eye, where it can modulate inflammation and neuroprotection. Understanding the precise molecular steps of GO:0036018 is critical for developing targeted therapies and for interpreting how genetic variants affect drug responses. The pathway is also relevant to cancer biology, as tumor-derived EPO can suppress anti-tumor immunity, suggesting that EPO signaling has context-dependent roles beyond red blood cell production. In diabetes, impaired EPO response to hypoxia may contribute to anemia and tissue hypoxia, further expanding the clinical importance of this GO term.
cellular response to erythropoietin At A Glance
| GO ID | GO:0036018 |
|---|---|
| GO term | cellular response to erythropoietin |
| Ontology | biological_process |
| Synonym | none |
| Major function | Mediates cellular changes in response to erythropoietin, including survival, proliferation, and differentiation of erythroid progenitors |
| Key receptor | Erythropoietin receptor (EPOR) |
| Major signaling pathway | JAK2/STAT5, PI3K/AKT, MAPK |
| Primary cell types | Erythroid progenitor cells, megakaryocytes, some non-hematopoietic cells |
| Disease relevance | Anemia, myelodysplastic syndromes, cancer, diabetes, glaucoma |
What Is GO:0036018?
GO:0036018, cellular response to erythropoietin, is defined as any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an erythropoietin stimulus. In practice, this includes receptor binding, activation of intracellular signaling cascades, modulation of transcription factors, and subsequent changes in cell behavior such as survival, proliferation, or differentiation.
Why Is cellular response to erythropoietin Important in Cell Biology?
The cellular response to erythropoietin is fundamental to red blood cell production and oxygen delivery, and its dysregulation underlies a wide range of hematological and non-hematological disorders. Therapeutic modulation of this pathway with erythropoiesis-stimulating agents is standard care for anemia in chronic kidney disease and myelodysplastic syndromes, yet many patients show resistance, underscoring the need to understand the molecular determinants of response. Moreover, emerging evidence links EPO signaling to immune regulation and cancer progression, making GO:0036018 a high-priority area for both basic and translational research.
• Essential for erythropoiesis and maintenance of red blood cell mass.
• Predicts response to erythropoiesis-stimulating agents in anemia management.
• Implicated in myelodysplastic syndromes and resistance to epoetin alfa.
• Tumor-derived EPO can suppress anti-tumor immunity, affecting cancer immunotherapy.
• Impaired EPO response to hypoxia is associated with type 2 diabetes.
• EPO signaling has neuroprotective and anti-inflammatory roles in glaucoma.
• Provides a model for studying cytokine receptor signaling and JAK/STAT pathways.
• Enables development of CRISPR-based disease models for anemia and related disorders.
What Happens During cellular response to erythropoietin?
Erythropoietin binding and receptor activation
In simple terms: EPO docks onto its receptor on the cell surface, causing the receptor to change shape and activate.
The cellular response to erythropoietin begins when EPO binds to the erythropoietin receptor (EPOR) on the surface of target cells, primarily erythroid progenitors. This binding induces a conformational change in EPOR, leading to receptor dimerization and activation of associated Janus kinase 2 (JAK2). Activated JAK2 phosphorylates tyrosine residues on the cytoplasmic domain of EPOR, creating docking sites for downstream signaling proteins.
JAK2/STAT5 signaling cascade
In simple terms: Activated JAK2 turns on STAT5, which travels to the nucleus and switches on genes that keep red blood cell precursors alive and dividing.
Phosphorylated EPOR recruits signal transducer and activator of transcription 5 (STAT5), which is then phosphorylated by JAK2. Phosphorylated STAT5 forms dimers, translocates to the nucleus, and activates transcription of target genes involved in erythroid survival, proliferation, and differentiation, such as BCL2L1 and BCL2. This pathway is the central axis of the cellular response to erythropoietin and is frequently dysregulated in hematological disorders.
PI3K/AKT and MAPK pathways
In simple terms: Other signaling routes help the cell survive and grow, complementing STAT5.
In addition to STAT5, EPO stimulation activates the phosphatidylinositol 3-kinase (PI3K)/AKT pathway and the mitogen-activated protein kinase (MAPK) cascade. These pathways promote cell survival, proliferation, and metabolic adaptation, and they cooperate with STAT5 to sustain erythropoiesis. The balance between these signals determines the overall cellular outcome of EPO stimulation.
Negative feedback and termination
In simple terms: The cell has brakes to stop the signal, preventing excessive red blood cell production.
The cellular response to erythropoietin is tightly regulated by negative feedback mechanisms, including the induction of suppressor of cytokine signaling (SOCS) proteins, particularly SOCS1 and SOCS3, which inhibit JAK2 activity. Additionally, protein tyrosine phosphatases such as SHP1 dephosphorylate JAK2 and EPOR, terminating the signal. Dysregulation of these feedback loops can lead to prolonged or excessive EPO signaling, contributing to disease.
Key Genes Involved in GO:0036018 cellular response to erythropoietin
The following genes and proteins are central to the cellular response to erythropoietin, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EPO | Ligand that binds EPOR to initiate signaling | Therapeutic target in anemia; tumor-derived EPO affects immunity |
| EPOR | Receptor for EPO; activates JAK2/STAT5 | Mutations linked to erythrocytosis and responsiveness to ESAs |
| JAK2 | Tyrosine kinase that phosphorylates EPOR and STAT5 | JAK2 V617F mutation in myeloproliferative neoplasms |
| STAT5A | Transcription factor mediating EPO-induced gene expression | Key effector of erythroid survival and differentiation |
| STAT5B | Transcription factor mediating EPO-induced gene expression | Cooperates with STAT5A in erythropoiesis |
| PIK3CA | Catalytic subunit of PI3K; activates AKT | Modulates survival signals downstream of EPOR |
| AKT1 | Serine/threonine kinase promoting cell survival | Mediates anti-apoptotic effects of EPO |
| MAPK1 | Extracellular signal-regulated kinase 2 (ERK2) | Transmits proliferative signals from EPOR |
| MAPK3 | Extracellular signal-regulated kinase 1 (ERK1) | Transmits proliferative signals from EPOR |
| SOCS1 | Negative regulator of JAK2 signaling | Feedback inhibitor of EPO response |
| SOCS3 | Negative regulator of JAK2 signaling | Feedback inhibitor of EPO response |
| PTPN6 | Protein tyrosine phosphatase SHP1; dephosphorylates JAK2 | Terminates EPO signaling |
| BCL2L1 | Anti-apoptotic protein (BCL-xL) induced by STAT5 | Promotes erythroid survival |
| GATA1 | Transcription factor essential for erythroid differentiation | Cooperates with STAT5 in EPO response |
| KIT | Stem cell factor receptor; modulates EPO response | Affects erythroid progenitor expansion |
| TFRC | Transferrin receptor; iron uptake for heme synthesis | Indirectly supports erythropoiesis |
| HBB | Beta-globin; component of hemoglobin | Marker of erythroid maturation |
How Is cellular response to erythropoietin Regulated?
The cellular response to erythropoietin is regulated at multiple levels. Receptor availability is controlled by EPOR expression and trafficking. Signaling intensity is modulated by negative feedback loops involving SOCS proteins and phosphatases. Additionally, cross-talk with other cytokines and growth factors, such as stem cell factor (SCF) and insulin-like growth factor 1 (IGF-1), fine-tunes the response. In disease states, chronic inflammation and uremic toxins can impair EPO signaling, leading to resistance to erythropoiesis-stimulating agents. Hypoxia-inducible factor (HIF) regulates EPO production, indirectly influencing the cellular response.
cellular response to erythropoietin and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EPO | Anemia of chronic disease; tumor immunosuppression | EPO knockout or overexpression in cancer cell lines |
| EPOR | Primary familial erythrocytosis; ESA resistance | EPOR point mutation knock-in in erythroid progenitors |
| JAK2 | Myeloproliferative neoplasms; MDS | JAK2 V617F knock-in mouse model |
| STAT5A | Erythroid failure; anemia | STAT5A knockout cell lines |
| SOCS1 | Inflammation-driven anemia | SOCS1 overexpression in erythroid cells |
Anemia and myelodysplastic syndromes
Defective or insufficient cellular response to erythropoietin contributes to anemia in chronic kidney disease and myelodysplastic syndromes (MDS). In MDS, erythroid progenitors often show impaired EPO signaling, leading to ineffective erythropoiesis. Clinical trials comparing luspatercept and epoetin alfa in lower-risk MDS have shown that targeting later stages of erythropoiesis can overcome some resistance to ESAs. Predictive markers of EPO response, such as serum EPO levels and iron status, are used to optimize treatment.
Cancer and immunosuppression
Tumor-derived erythropoietin can act as an immunosuppressive switch in the tumor microenvironment, promoting immune evasion. This non-erythropoietic role of EPO signaling highlights the importance of understanding GO:0036018 in cancer biology and immunotherapy. Targeting EPO/EPOR signaling in tumors may enhance anti-tumor immunity.
Diabetes and metabolic stress
Impaired erythropoietin response to hypoxia has been observed in type 2 diabetes, potentially contributing to anemia and tissue hypoxia. This suggests that metabolic disorders can disrupt the cellular response to EPO, and that HIF/EPO axis dysfunction may be a therapeutic target.
Glaucoma and neuroprotection
Erythropoietin signaling has been studied in glaucoma, where it may exert neuroprotective and anti-inflammatory effects. The cellular response to EPO in retinal ganglion cells involves similar signaling pathways, suggesting broader roles beyond erythropoiesis.
From cellular response to erythropoietin-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does EPOR mutation affect EPO-induced STAT5 activation? | Point mutation knock-in of EPOR in erythroid cell line |
| What is the role of JAK2 in EPO response? | JAK2 knockout in UT-7 or HEL cells |
| Can overexpression of EPO enhance tumor immunosuppression? | EPO overexpression in melanoma or breast cancer models |
| How does SOCS1 feedback regulate EPO signaling? | SOCS1 knockout or overexpression in erythroid progenitors |
| Does a disease-associated STAT5A variant alter erythropoiesis? | Knock-in of STAT5A variant in CD34+ cells |
| What genes are essential for EPO response? | Genome-wide CRISPR knockout library screening in EPO-dependent cells |
How to Study the cellular response to erythropoietin Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify EPO-induced transcriptional programs |
| Phospho-proteomics | Phosphorylation of signaling proteins | Map JAK2/STAT5 activation dynamics |
| Flow cytometry | Cell surface markers and viability | Assess erythroid differentiation and survival |
| Phospho-flow | STAT5 phosphorylation at single-cell level | Quantify signaling heterogeneity |
| CRISPR knockout screen | Gene essentiality for EPO response | Discover novel regulators |
| Western blot | Protein expression and phosphorylation | Validate specific signaling events |
| Reporter assays | Transcriptional activity of STAT5 | Measure EPO-induced gene expression |
Transcriptomic analysis (RNA-seq)
RNA sequencing can quantify changes in gene expression following EPO stimulation, revealing transcriptional programs downstream of STAT5 and other factors. This method is useful for identifying EPO-responsive genes and for comparing wild-type and mutant cells.
Proteomic analysis
Mass spectrometry-based proteomics can measure phosphorylation events and protein-protein interactions in the EPO signaling cascade. This helps map the dynamic changes in signaling networks after EPO stimulation.
Flow cytometry and phospho-flow
Flow cytometry can assess erythroid differentiation markers and cell survival after EPO treatment. Phospho-flow allows quantification of phosphorylated STAT5 at the single-cell level, providing insights into signaling heterogeneity.
CRISPR screening
Genome-wide CRISPR knockout screens in EPO-dependent cell lines can identify genes required for EPO response and resistance. This approach is powerful for discovering novel regulators of GO:0036018.
How CRISPR Can Be Used to Study GO:0036018 cellular response to erythropoietin
Knockout
CRISPR knockout of EPOR, JAK2, or STAT5A in erythroid cell lines can abolish EPO response, confirming their essential roles. Knockout models are also used to study negative regulators like SOCS1.
Point Mutation
Introducing point mutations such as JAK2 V617F or EPOR truncations via CRISPR can model disease-associated variants and dissect their impact on EPO signaling. These models help understand resistance to ESAs.
Knock-in
Knock-in of tagged EPOR or STAT5A allows tracking of protein localization and interactions in live cells. This approach can also be used to introduce human disease mutations into cell lines.
Overexpression
Overexpression of EPO or EPOR via CRISPR activation or lentiviral delivery can enhance EPO response and model tumor-derived EPO immunosuppression. Overexpression models are useful for studying gain-of-function effects.
How EDITGENE Supports cellular response to erythropoietin Research
Researchers studying cellular response to erythropoietin-related genes often need to determine whether a candidate gene is causally involved in EPO signaling, disease resistance, or immune modulation. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for cellular response to erythropoietin research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CD40 Knockout HEK293 Cell Line | EDJ-KQ553 | Human | 958 | Details Get a Quote |
| RHEX Knockout HEK293 Cell Line | EDJ-KQ15062 | Human | 440712 | Details Get a Quote |
| CD40 Knockout A-549 Cell Line | EDJ-KQ18027 | Human | 958 | Details Get a Quote |
| CD40 Knockout HCT 116 Cell Line | EDJ-KQ18925 | Human | 958 | Details Get a Quote |
| MT1X Knockout HEK293 Cell Line | EDJ-KQ50455 | Human | 4501 | Details Get a Quote |
| MT2A Knockout HEK293 Cell Line | EDJ-KQ50456 | Human | 4502 | Details Get a Quote |
| CD40 Knockout HeLa Cell Line | EDJ-KQ52841 | Human | 958 | Details Get a Quote |
| MT1X Knockout HeLa Cell Line | EDJ-KQ53913 | Human | 4501 | Details Get a Quote |
| MT2A Knockout HeLa Cell Line | EDJ-KQ53914 | Human | 4502 | Details Get a Quote |
| RHEX Knockout HeLa Cell Line | EDJ-KQ60403 | Human | 440712 | Details Get a Quote |
| MT1X Knockout A-549 Cell Line | EDJ-KQ62406 | Human | 4501 | Details Get a Quote |
| MT2A Knockout A-549 Cell Line | EDJ-KQ62407 | Human | 4502 | Details Get a Quote |
| RHEX Knockout A-549 Cell Line | EDJ-KQ68871 | Human | 440712 | Details Get a Quote |
| MT1X Knockout HCT 116 Cell Line | EDJ-KQ70873 | Human | 4501 | Details Get a Quote |
| MT2A Knockout HCT 116 Cell Line | EDJ-KQ70874 | Human | 4502 | Details Get a Quote |
Displaying Records 1 To 15 Of 16 Records
Frequently Asked Questions About cellular response to erythropoietin
What is GO:0036018?
GO:0036018 is the Gene Ontology term for cellular response to erythropoietin, describing all cellular changes triggered by erythropoietin stimulation.
What genes are involved in cellular response to erythropoietin?
Key genes include EPO, EPOR, JAK2, STAT5A, STAT5B, PI3K, AKT1, MAPK1, MAPK3, SOCS1, SOCS3, and PTPN6.
How does erythropoietin signal inside the cell?
EPO binds EPOR, activating JAK2, which phosphorylates STAT5 and other pathways to drive survival, proliferation, and differentiation.
What diseases are linked to defective erythropoietin response?
Anemia, myelodysplastic syndromes, cancer immunosuppression, diabetes, and glaucoma have been linked to altered EPO signaling.
Can CRISPR be used to study erythropoietin response?
Yes, CRISPR knockout, knock-in, and point mutation models are widely used to dissect EPO signaling components.
What is the role of STAT5 in erythropoietin response?
STAT5 is a transcription factor activated by JAK2 that induces genes promoting erythroid survival and differentiation.
How is erythropoietin response measured in the lab?
Common methods include RNA-seq, phospho-flow, Western blot, and flow cytometry to assess signaling and differentiation.
What is the difference between EPO and EPOR?
EPO is the ligand (hormone), while EPOR is the receptor that binds EPO and initiates intracellular signaling.
Why do some patients not respond to erythropoietin therapy?
Resistance can arise from defects in EPOR signaling, iron deficiency, inflammation, or other factors.
What model systems are used to study GO:0036018?
Erythroid cell lines (e.g., UT-7, HEL), primary CD34+ cells, and mouse models with CRISPR edits are commonly used.
Conclusion
The cellular response to erythropoietin (GO:0036018) is a critical biological process that governs red blood cell production and has broader implications in immunity, cancer, and metabolic disease. Understanding its molecular players and regulatory mechanisms is essential for developing improved therapies for anemia and related disorders. CRISPR-based models offer powerful tools to dissect this pathway and identify new therapeutic targets.
References
- 1. Chiu DK et al.. 2025. Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity.. Science 388(6745):eadr3026 PMID: 40273234
- 2. Wojan F et al.. 2024. Impaired erythropoietin response to hypoxia in type 2 diabetes.. Acta Diabetol 61(7):925-932 PMID: 38570345
- 3. Della Porta MG et al.. 2024. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.. Lancet Haematol 11(9):e646-e658 PMID: 39038479
- 4. Platzbecker U et al.. 2023. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.. Lancet 402(10399):373-385 PMID: 37311468
- 5. Garcia-Manero G et al.. 2025. Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.. Adv Ther 42(7):3576-3589 PMID: 40377899
- 6. Beguin Y. 1998. Prediction of response to optimize outcome of treatment with erythropoietin.. Semin Oncol 25(3 Suppl 7):27-34 PMID: 9671327
- 7. Lai YF et al.. 2023. Erythropoietin in Glaucoma: From Mechanism to Therapy.. Int J Mol Sci 24(3) PMID: 36769310
- 8. Korzeniewski SJ et al.. 2017. Endogenous Erythropoietin.. Vitam Horm 105:39-56 PMID: 28629524
